-+ 0.00%
-+ 0.00%
-+ 0.00%

Benitec Biopharma BB-301 Phase 1b/2a Late-Breaking Abstract Accepted At 2026 Muscular Dystrophy Association Clinical And Scientific Conference

Benzinga·02/23/2026 12:06:51
Listen to the news

-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026-